Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sleep

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Clinical Drug Investigation|September 12, 2008
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programmePeter H Jones, Harold E Bays, Michael H Davidson, et al.
The American Journal of Cardiology|February 7, 2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemiaAnne C Goldberg, Harold E Bays, Christie M Ballantyne, et al.
Journal of Clinical Pharmacology|October 28, 2008
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humansTong Zhu, Walid M Awni, Balakrishna Hosmane, et al.
Atherosclerosis|November 11, 2008
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 studyPeter H Jones, Michael H Davidson, Moti L Kashyap, et al.
Journal of Clinical Pharmacology|March 29, 2007
Dual effects of rifampin on the pharmacokinetics of atrasentanHao Xiong, Robert A Carr, Charles S Locke, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Journal of Clinical Lipidology|February 5, 2011
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemiaHarold E Bays, Peter H Jones, Syed M Mohiuddin, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studiesPeter H Jones, Michael H Davidson, Anne C Goldberg, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Clinical Drug Investigation|September 12, 2008
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programmePeter H Jones, Harold E Bays, Michael H Davidson, et al.
The American Journal of Cardiology|February 7, 2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemiaAnne C Goldberg, Harold E Bays, Christie M Ballantyne, et al.
Journal of Clinical Pharmacology|October 28, 2008
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humansTong Zhu, Walid M Awni, Balakrishna Hosmane, et al.
Atherosclerosis|November 11, 2008
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 studyPeter H Jones, Michael H Davidson, Moti L Kashyap, et al.
Journal of Clinical Pharmacology|March 29, 2007
Dual effects of rifampin on the pharmacokinetics of atrasentanHao Xiong, Robert A Carr, Charles S Locke, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Journal of Clinical Lipidology|February 5, 2011
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemiaHarold E Bays, Peter H Jones, Syed M Mohiuddin, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studiesPeter H Jones, Michael H Davidson, Anne C Goldberg, et al.
Pageof 8